menu
    • menu
    [{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"EIC fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Grapiprant","moa":"Prostanoid EP4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Arctic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Arctic Therapeutics \/ EIC fund","highestDevelopmentStatusID":"8","companyTruncated":"Arctic Therapeutics \/ EIC fund"},{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Arctic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arctic Therapeutics \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arctic Therapeutics \/ Arctic Therapeutics"},{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Arctic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arctic Therapeutics \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arctic Therapeutics \/ Arctic Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Arctic Therapeutics

    Menu

    Arctic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grapiprant

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : EIC fund

                            Deal Size : $27.7 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

                            Details : The financing aims to fund the development of AT-001 an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain. It is being evaluated for treating HCCAA.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 22, 2025

                            Lead Product(s) : Grapiprant

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : EIC fund

                            Deal Size : $27.7 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-Acetylcysteine Amide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Recipient : Nacuity Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arctic and Nacuity Announce EMA Approval to Initiate Trial of AT-001 for HCCAA

                            Details : NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : N-Acetylcysteine Amide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Recipient : Nacuity Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Arctic Therapeutics

                            Iceland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-Acetylcysteine Amide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Recipient : Nacuity Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop...

                            Details : NPI-001 is a differentiated, purified, prescription-quality, GMP-grade N-acetylcysteine amide (NACA) being developed to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 13, 2022

                            Lead Product(s) : N-Acetylcysteine Amide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Recipient : Nacuity Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth